<!DOCTYPE  html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang=""><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"/><title>标题</title><style type="text/css">.title
{
  font-family: Arial, Helvetica, sans-serif;
   font-size: 14px;
   font-weight: bold;
   color: #000000;
   text-decoration: none;
   margin: 1pt;
   text-align: left;
   position: fixed;
   white-space:nowrap;
   width: 10px;
   height: 10px;
   writing-mode:tb-rl;
   -webkit-transform:rotate(90deg);
   -moz-transform:rotate(90deg);
   -o-transform: rotate(90deg);
}
.data
{
   margin: 1pt;
   text-align: left;
   padding-top: 3pt;
   margin-left: 12pt;
}
a
{
   font-family: Arial, Helvetica, sans-serif;
   font-size: 14px;
   font-weight: normal;
   color: #0f0f0f;
   background-color: #a0a0a0;
   text-decoration: underline;
   cursor: pointer;
   margin: 1pt;
}
span
{
   margin: 1pt;
}
a
{
display: block;
}
</style></head><body><div class="title">标题</div><div class="data"><a target="content" href="content.htm#a0" style="padding-left: 10pt;">Multicenter AIDS Cohort Study (MACS)</a><a target="content" href="content.htm#a1" style="padding-left: 60pt;">7087 MSM enrolled in US</a><a target="content" href="content.htm#a2" style="padding-left: 90pt;">4954 in 1984-85</a><a target="content" href="content.htm#a3" style="padding-left: 10pt;">MACS Working Groups</a><a target="content" href="content.htm#a4" style="padding-left: 90pt;"> Aging ( J. Margolick)</a><a target="content" href="content.htm#a5" style="padding-left: 90pt;">Cardiovascular disease</a><a target="content" href="content.htm#a6" style="padding-left: 70pt;">Physical Exam / Lipodystrophy Exam</a><a target="content" href="content.htm#a7" style="padding-left: 70pt;">Quality of Life* (SF36)</a><a target="content" href="content.htm#a8" style="padding-left: 10pt;">Administrative Forms</a><a target="content" href="content.htm#a9" style="padding-left: 30pt;">Data Set Transmission</a><a target="content" href="content.htm#a10" style="padding-left: 60pt;">Planning and design of studies</a><a target="content" href="content.htm#a11" style="padding-left: 90pt;">Form development</a><a target="content" href="content.htm#a12" style="padding-left: 40pt;">Histogram of 1222 CD4+ Regression Slopes Among HIV-1 Seropositive Men, 1984-1996</a><a target="content" href="content.htm#a13" style="padding-left: 80pt;">Likelihood of Developing AIDS in HIV Infected Individuals with 200 &lt; CD4 &lt; 350 in the Non-HAART Era</a><a target="content" href="content.htm#a14" style="padding-left: 50pt;">Multicenter AIDS Cohort Study</a><a target="content" href="content.htm#a15" style="padding-left: 50pt;">Likelihood of Developing AIDS in Six Years</a><a target="content" href="content.htm#a16" style="padding-left: 50pt;">Likelihood of Developing AIDS in Six Years</a><a target="content" href="content.htm#a17" style="padding-left: 50pt;">Likelihood of Developing AIDS in Nine Years</a><a target="content" href="content.htm#a18" style="padding-left: 60pt;">Proportion Surviving AIDS by Year of Diagnosis</a><a target="content" href="content.htm#a19" style="padding-left: 50pt;">Time to Death According to GBV-C Serostatus Early and Late in HIV Infection</a><a target="content" href="content.htm#a20" style="padding-left: 60pt;">HAART Use in the Multicenter AIDS Cohort Study</a><a target="content" href="content.htm#a21" style="padding-left: 30pt;">Adherence to HIV-Antiretroviral Therapies</a><a target="content" href="content.htm#a22" style="padding-left: 30pt;">CD4 Cell Count in</a><a target="content" href="content.htm#a23" style="padding-left: 30pt;">Use of Antiretroviral Therapy and Effectiveness at the Population Level</a><a target="content" href="content.htm#a24" style="padding-left: 20pt;">AIDS-Free Time by Calendar</a><a target="content" href="content.htm#a25" style="padding-left: 20pt;">Survival Time by Calendar</a><a target="content" href="content.htm#a26" style="padding-left: 60pt;">Time to AIDS by CD4 Cell Count at Time of Treatment Adjusting for Individual Lead Time</a><a target="content" href="content.htm#a27" style="padding-left: 60pt;">Corresponding Hazards of Death after AIDS Diagnosis from Weibull Models</a><a target="content" href="content.htm#a28" style="padding-left: 60pt;">Estimated Cause-Specific Mortality after 35 Years of Age by HAART Era in the MACS, 1984-2008</a><a target="content" href="content.htm#a29" style="padding-left: 60pt;">Prognostic Value of the CD4 Cell Count and HIV RNA attained by HAART-Treated Individuals</a><a target="content" href="content.htm#a30" style="padding-left: 60pt;">Risk of AIDS or Death by CD4 Cell Count while Plasma Viral Load was &lt;50 HIV RNA copies/mL</a><a target="content" href="content.htm#a31" style="padding-left: 20pt;">Infection of Dendritic Cells with HHV-8 is Blocked by anti-DC-SIGN mAb</a><a target="content" href="content.htm#a32" style="padding-left: 20pt;">Infection of Macrophages with HHV-8 is Blocked by anti-DC-SIGN mAb</a><a target="content" href="content.htm#a33" style="padding-left: 90pt;">Prevalence of Systolic Hypertension (SH) and Diastolic Hypertension (DH) by HIV Sero-status and Therapy, and Relative to the Time of HAART Initiation</a><a target="content" href="content.htm#a34" style="padding-left: 90pt;">Multiple Regression Analyses:</a><a target="content" href="content.htm#a35" style="padding-left: 90pt;">Association between CD4+ T-cell Count (cells/µℓ) and Prevalence of Carotid Lesions among Participants in Men (MACS) and Women (WIHS)</a><a target="content" href="content.htm#a36" style="padding-left: 60pt;">MACS</a><a target="content" href="content.htm#a37" style="padding-left: 60pt;">Categorization of Hepatic Fibrosis by HIV and Viral Hepatitis Disease Category</a><a target="content" href="content.htm#a38" style="padding-left: 60pt;">Time Trend in Liver-Related Mortality Rates by Hepatitis and HIV-1 Status</a><a target="content" href="content.htm#a39" style="padding-left: 60pt;">CXCL13 Levels in HIV-Positive Non-Hodgkin Lymphoma Cases and Controls</a><a target="content" href="content.htm#a40" style="padding-left: 60pt;">CXCL13 Levels by CXCL13 and CXCR5 tagSNPs</a><a target="content" href="content.htm#a41" style="padding-left: 60pt;">Time Free of Anal Cancer</a><a target="content" href="content.htm#a42" style="padding-left: 60pt;">Mean Trail-Making B Scores Around HIV-1 Seroconversion</a><a target="content" href="content.htm#a43" style="padding-left: 60pt;">Mean Symbol-Digit Scores Around HIV-1 Seroconversion</a><a target="content" href="content.htm#a44" style="padding-left: 60pt;">Surface Rendering of the Independent Effects of HIV Serostatus and Age on Grey Matter Volume</a><a target="content" href="content.htm#a45" style="padding-left: 60pt;">Goodness of Fit for log10(HIV NRA) as a Mixture of Two Normal Distributions - MACS</a><a target="content" href="content.htm#a46" style="padding-left: 60pt;">Goodness of Fit for log10(HIV NRA) as a Mixture of Two Normal Distributions - WIHS</a><a target="content" href="content.htm#a47" style="padding-left: 60pt;">Bimodel Distributions of log10(HIV RNA in copies/ml) for the MACS and WIHS</a><a target="content" href="content.htm#a48" style="padding-left: 30pt;">Risk and Survival Attributable to the Absence of HAART</a></div></body></html>
